Meyer 2011.
Trial name or title | "Effect of low molecular weight heparin on survival of stage I, II or IIIA non small cell lung cancer. A multicenter, open, randomised controlled trial" |
Methods | Phase III, prospective, multicentric, randomised, open trial in parallel groups with a blind adjudication of all endpoint criteria |
Participants | Patients with completely resected non‐small cell lung cancer of stage I, II, or IIIA T3N1 confirmed by histology. Patients who had preoperative chemotherapy, those who are selected for adjuvant chemotherapy and those who are not candidates for adjuvant chemotherapy (because they have a contraindication to chemotherapy or they have a stage I cancer) are eligible for the study |
Interventions | Tinzaparin sodium 100 UI/kg od for 12 weeks along with usual postoperative care including chemotherapy Control: usual postoperative care including chemotherapy |
Outcomes | Primary endpoint: overall 3‐year mortality Secondary outcomes: major bleeding time, symptomatic VTE, cancer‐related mortality, disease‐free survival |
Starting date | June 2007 |
Contact information | Guy Meyer guy.meyer@egp.aphp.fr |
Notes | ClinicalTrials.gov Identifier: NCT00475098 |